Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02683369 · ClinicalTrials.gov registry record · Phase 2

Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women

A Phase 2 study, sponsored by University of Maryland, Baltimore.

Completed
Registry status
Phase 2
Development phase
23
Enrollment target

NCT02683369 is a Phase 2 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 23 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02683369, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.

COMPLETED
Registry status
Phase 2
Development phase
23 participants
Enrollment target

Study Summary

Healthy premenopausal women that are iron-deficient without anemia will receive a low-dose iron dietary supplement. The investigators seek to determine if the low-dose iron dietary supplement will restore iron levels to normal range with fewer side effects than typically experienced at higher doses of iron supplementation.

Interventions

  • DIETARY_SUPPLEMENT Blood Builder®/Iron Response®

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2016-02
Est. Completion 2017-05
Phase Phase 2

Sponsor

University of Maryland, Baltimore

560 total trials

What the Registry Record Tells You About NCT02683369

The ClinicalTrials.gov registry entry for NCT02683369 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Blood Builder®/Iron Response® is the first listed.

NCT02683369 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02683369 about?

NCT02683369 is a clinical study titled "Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women". Healthy premenopausal women that are iron-deficient without anemia will receive a low-dose iron dietary supplement. The investigators seek to determine if the low-dose iron dietary supplement will restore iron levels to normal range with fewer side effects than typically experienced at higher doses ...

What is the current status of trial NCT02683369?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2016-02. Estimated completion is 2017-05.

What interventions are being tested in trial NCT02683369?

The interventions under investigation include: Blood Builder®/Iron Response® (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02683369?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.